Systemic therapy for metastatic malignant melanoma--from deeply disappointing to bright future?

2.50
Hdl Handle:
http://hdl.handle.net/10541/59153
Title:
Systemic therapy for metastatic malignant melanoma--from deeply disappointing to bright future?
Authors:
Lorigan, Paul C ( 0000-0002-8875-2164 ) ; Eisen, Tim; Hauschild, Axel
Abstract:
The last decade has seen a considerable improvement in the understanding of the biology of melanoma. Advances have come in the understanding of the importance of critical oncogenes and tumour suppressor genes, epigenetic phenomena, signalling pathways, drug resistance mechanisms, the pivotal role of the local immune system, and the importance of cell-cell and cell-matrix interactions. Many of these pathways and interactions include potentially 'drugable' targets. These developments have allowed the identification and/or design of a range of new, targeted therapies. Evaluation of these new drugs has brought a whole new series of challenges. These include identification of appropriate pre-clinical models, overcoming the redundancy in-built in complex biological systems, identification of appropriate molecular and clinical endpoints to show that the drug is hitting the target, how to combine treatments, and new toxicities. For the first time, there is the possibility of personalized treatment for melanoma patients, based on individual host and tumour characteristics. This paper discusses the range of new drugs and targets have been identified, the outcome of clinical trials, and the directions for future advances.
Affiliation:
CRUK Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester, UK. paul.lorigan@manchester.ac.uk
Citation:
Systemic therapy for metastatic malignant melanoma--from deeply disappointing to bright future? 2008, 17 (5):383-94 Exp. Dermatol.
Journal:
Experimental Dermatology
Issue Date:
May-2008
URI:
http://hdl.handle.net/10541/59153
DOI:
10.1111/j.1600-0625.2007.00673.x
PubMed ID:
18312390
Type:
Article
Language:
en
ISSN:
1600-0625
Appears in Collections:
All Christie Publications ; Medical Oncology

Full metadata record

DC FieldValue Language
dc.contributor.authorLorigan, Paul C-
dc.contributor.authorEisen, Tim-
dc.contributor.authorHauschild, Axel-
dc.date.accessioned2009-04-02T15:59:15Z-
dc.date.available2009-04-02T15:59:15Z-
dc.date.issued2008-05-
dc.identifier.citationSystemic therapy for metastatic malignant melanoma--from deeply disappointing to bright future? 2008, 17 (5):383-94 Exp. Dermatol.en
dc.identifier.issn1600-0625-
dc.identifier.pmid18312390-
dc.identifier.doi10.1111/j.1600-0625.2007.00673.x-
dc.identifier.urihttp://hdl.handle.net/10541/59153-
dc.description.abstractThe last decade has seen a considerable improvement in the understanding of the biology of melanoma. Advances have come in the understanding of the importance of critical oncogenes and tumour suppressor genes, epigenetic phenomena, signalling pathways, drug resistance mechanisms, the pivotal role of the local immune system, and the importance of cell-cell and cell-matrix interactions. Many of these pathways and interactions include potentially 'drugable' targets. These developments have allowed the identification and/or design of a range of new, targeted therapies. Evaluation of these new drugs has brought a whole new series of challenges. These include identification of appropriate pre-clinical models, overcoming the redundancy in-built in complex biological systems, identification of appropriate molecular and clinical endpoints to show that the drug is hitting the target, how to combine treatments, and new toxicities. For the first time, there is the possibility of personalized treatment for melanoma patients, based on individual host and tumour characteristics. This paper discusses the range of new drugs and targets have been identified, the outcome of clinical trials, and the directions for future advances.en
dc.language.isoenen
dc.subjectSkin Canceren
dc.subjectMetastaticen
dc.subjectTargeted Therapyen
dc.subjectGenes, Tumour Suppressor-
dc.subject.meshAngiogenesis Inhibitors-
dc.subject.meshAntineoplastic Agents-
dc.subject.meshApoptosis-
dc.subject.meshDrug Resistance, Neoplasm-
dc.subject.meshDrug Therapy, Combination-
dc.subject.meshGenes, Tumor Suppressor-
dc.subject.meshHumans-
dc.subject.meshImmunologic Factors-
dc.subject.meshImmunotherapy-
dc.subject.meshMelanoma-
dc.subject.meshSignal Transduction-
dc.subject.meshSkin Neoplasms-
dc.titleSystemic therapy for metastatic malignant melanoma--from deeply disappointing to bright future?en
dc.typeArticleen
dc.contributor.departmentCRUK Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester, UK. paul.lorigan@manchester.ac.uken
dc.identifier.journalExperimental Dermatologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.